TY - JOUR T1 - Study protocol for the development and internal validation of SPIRIT (Schizophrenia Prediction of Resistance to Treatment): A clinical tool for predicting risk of treatment resistance to anti-psychotics in First Episode Schizophrenia JF - medRxiv DO - 10.1101/2022.02.15.22270460 SP - 2022.02.15.22270460 AU - Saeed Farooq AU - Miriam Hattle AU - Paola Dazzan AU - Tom Kingstone AU - Olesya Ajnakina AU - David Shiers AU - Maria Antonietta Nettis AU - Andrew Lawrence AU - Richard D. Riley AU - Danielle A. van der Windt Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/15/2022.02.15.22270460.abstract N2 - Introduction Treatment Resistant Schizophrenia (TRS) is associated with significant impairment of functioning and high treatment costs. Identification of patients at high risk of TRS at their initial diagnosis may significantly improve clinical outcomes and minimize social and functional disability. We aim to develop a prognostic model for predicting the risk of TRS in patients with First Episode Schizophrenia, and to examine its potential utility and acceptability as a clinical decision tool.Methods and analysis We will use two well-characterised UK-based first episode psychosis cohorts: AESOP-10 and GAP for which data has been collected on sociodemographic and clinical characteristics. We will identify candidate predictors for the model based on current literature and stakeholder consultation. Model development will use all data, with the number of candidate predictors restricted according to available sample size and event rate. A model for predicting risk of TRS will be developed based on penalised regression, with missing data handled using multiple imputation. Internal validation will be undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model’s performance. The clinical utility of the model in terms of clinically relevant risk thresholds will be evaluated using net benefit and decision curves (comparative to competing strategies). Consultation with patients and clinical stakeholders will determine potential thresholds of risk for treatment decision making. The acceptability of embedding the model as a clinical tool will be explored using focus groups with clinicians in early intervention services.Ethics and dissemination The development of the prognostic model will be based on anonymised data from existing cohorts, for which ethical approval is in place. Ethical approval has been obtained from Keele University for the qualitative focus groups within Early Intervention in Psychosis services (Ref: MH-210174). Findings will be shared through peer-review publications, conference presentations and social media. A lay summary will be published on collaborator websites.Strengths and limitations of this studyThe proposed study is the first step on the road towards the design and evaluation of a prognostic model and decision tool for the identification of treatment resistant schizophrenia. This could be informative to clinicians, patients, and their care providers in shared decision making and improvement of treatment plans.Individual participant data from two existing cohorts will be used to develop and internally validate the prognostic model.Using a mixed method design improves the ability to understand the limitations of the tool in a clinical context and create a foundation to develop it to be more effective.A limitation of the development of this tool is that the number of people with TRS may not be sufficiently large to consider all potential predictors for the modelFurther testing of the external validity of the prognostic model will be requiredCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis Study was funded by the NIHRAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health research authority - 21/HRA/3472 gave ethical approval for this work Keele University FMHS Faculty Research Ethics Committee - MH-210174 - gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is inapplicable as this is a protocol paper and data has not yet been produced ER -